WO1999003976A3 - Method of treating leukocytes, leukocyte compositions and methods of use thereof - Google Patents

Method of treating leukocytes, leukocyte compositions and methods of use thereof Download PDF

Info

Publication number
WO1999003976A3
WO1999003976A3 PCT/US1998/015067 US9815067W WO9903976A3 WO 1999003976 A3 WO1999003976 A3 WO 1999003976A3 US 9815067 W US9815067 W US 9815067W WO 9903976 A3 WO9903976 A3 WO 9903976A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
leukocytes
leukocyte
treating
Prior art date
Application number
PCT/US1998/015067
Other languages
French (fr)
Other versions
WO1999003976A2 (en
Inventor
William M Greenman
Joshua A Grass
Sohel Talib
Adonis Stassinopoulos
Derek J Hei
John E Hearst
Original Assignee
Cerus Corp
William M Greenman
Joshua A Grass
Sohel Talib
Adonis Stassinopoulos
Derek J Hei
John E Hearst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp, William M Greenman, Joshua A Grass, Sohel Talib, Adonis Stassinopoulos, Derek J Hei, John E Hearst filed Critical Cerus Corp
Priority to CA002296366A priority Critical patent/CA2296366A1/en
Priority to JP2000503182A priority patent/JP2003520563A/en
Priority to EP98936943A priority patent/EP1005531A2/en
Priority to AU85776/98A priority patent/AU748074B2/en
Publication of WO1999003976A2 publication Critical patent/WO1999003976A2/en
Publication of WO1999003976A3 publication Critical patent/WO1999003976A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods and compositions for treating leukocytes to arrest proliferation of the leukocytes and render them ineffective in eliciting graft-versus-host disease (GVHD), but effective to enhance engraftment of allongeneic donor cells and promote destruction of diseased cells or pathogens. Leukocyte compositions and methods of use of these compositions in alleviating disease, facilitating various types of immune reconstitution and immunotherapy, and enhancing engraftment of allogeneic donor cells, are also provided.
PCT/US1998/015067 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof WO1999003976A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002296366A CA2296366A1 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof
JP2000503182A JP2003520563A (en) 1997-07-21 1998-07-21 Methods for treating leukocytes, leukocyte compositions and methods of using the same
EP98936943A EP1005531A2 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof
AU85776/98A AU748074B2 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5359997P 1997-07-21 1997-07-21
US60/053,599 1997-07-21
US11970798A 1998-07-20 1998-07-20
US09/119,707 1998-07-20

Publications (2)

Publication Number Publication Date
WO1999003976A2 WO1999003976A2 (en) 1999-01-28
WO1999003976A3 true WO1999003976A3 (en) 1999-05-27

Family

ID=26732039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015067 WO1999003976A2 (en) 1997-07-21 1998-07-21 Method of treating leukocytes, leukocyte compositions and methods of use thereof

Country Status (6)

Country Link
EP (1) EP1005531A2 (en)
JP (1) JP2003520563A (en)
CN (1) CN1270630A (en)
AU (1) AU748074B2 (en)
CA (1) CA2296366A1 (en)
WO (1) WO1999003976A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409564B2 (en) 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
WO2001024824A1 (en) * 1999-10-05 2001-04-12 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
WO2002036748A2 (en) * 2000-11-03 2002-05-10 Nexell Therapeutics, Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
DE10112851C1 (en) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogeneic anti-tumor vaccine with HLA-haplo-identical antigen-presenting cells
KR101173871B1 (en) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 Modified free-living microbes vaccine compositions and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4545151B2 (en) 2003-02-06 2010-09-15 シーラス コーポレイション Listeria attenuated for entry into non-phagocytic cells, vaccines containing the Listeria, and methods of use thereof
US8697854B2 (en) 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
DE102011085695A1 (en) * 2011-11-03 2013-05-08 Jörg Pohl One-time dosed oxazaphosphorines for the treatment of diseases
US20190224494A1 (en) * 2012-03-20 2019-07-25 Fenwal, Inc. Apparatus and method for batch photoactivation of mononuclear cells with cryopreservation
US20130252227A1 (en) * 2012-03-20 2013-09-26 Fenwal, Inc. Apparatus and Method for Providing Cryopreserved ECP-Treated Mononuclear Cells
WO2016073381A1 (en) * 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
EP3058957A1 (en) * 2015-02-19 2016-08-24 Kiadis Pharma Intellectual Property BV Improved photodynamic process and product obtained therefrom
CN104788373A (en) * 2015-05-06 2015-07-22 武汉大学 Method for synthesizing compound S-303 hydrochloride
WO2016210374A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10898522B2 (en) 2015-08-19 2021-01-26 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
CA3003097A1 (en) 2015-10-23 2017-04-27 Cerus Corporation Plasma compositions and methods of use thereof
BR112019018273A2 (en) 2017-03-03 2020-07-14 Cerus Corporation kits and methods for preparing pathogen inactivated platelet compositions
US11679193B2 (en) 2017-12-20 2023-06-20 Fenwal, Inc. System and method of collecting and infusing an apoptotic white blood cell component and a transplant component
BR112020013178A2 (en) 2017-12-29 2020-12-01 Cerus Corporation systems and methods for the treatment of biological fluids
FR3082730B1 (en) * 2018-06-21 2022-04-22 Med Inn Pharma METHOD OF RESOLVING PRO-TUMOR INFLAMMATION USING A PHARMACEUTICAL PREPARATION
CN109337758A (en) * 2018-11-30 2019-02-15 广西科技大学 A kind of grease aflatoxin capture removing method for strengthening DNA and aflatoxin packing interaction based on ultraviolet light
EP3986499A2 (en) 2019-06-22 2022-04-27 Cerus Corporation Biological fluid treatment systems
EP3991179A1 (en) 2019-06-28 2022-05-04 Cerus Corporation System and methods for implementing a biological fluid treatment device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284409A2 (en) * 1987-03-27 1988-09-28 THERAKOS, Inc. Active specific immune suppression
WO1996039820A1 (en) * 1995-06-07 1996-12-19 Cerus Corporation Methods of inactivating leukocytes and inhibiting cytokine production in blood products
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284409A2 (en) * 1987-03-27 1988-09-28 THERAKOS, Inc. Active specific immune suppression
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation
WO1996039820A1 (en) * 1995-06-07 1996-12-19 Cerus Corporation Methods of inactivating leukocytes and inhibiting cytokine production in blood products

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GAUS H. ET AL.: "Superantigen-induced anergy of Vbeta8sup + CD4sup + T cells induces functional but non-proliferative T cells in vivo", IMMUNOLOGY, vol. 83, no. 3, 1994, gb, pages 333 - 340, XP002094963 *
GRASS J. ET AL.: "Inactivation of T-cells with psoralens and UVA in human platelet concentrates", BLOOD, vol. 86, no. 10 suppl.1, - 1995, pages 542a, XP002094969 *
GRASS J. ET AL.: "Prevention of transfusion-associated graft versus host disease (TA-GVHD) by photochemical treatment", BLOOD, vol. 88, no. 10 Suppl.1, 1996, pages 627a, XP002094968 *
GRASS J.A. ET AL.: "Inactivation of leucocytes in platelet concentrates by photochemical treatment with psoralen plus UVA", BLOOD, vol. 91, no. 6, 1998, pages 2180 - 2188, XP002094967 *
HALSTENSEN T., BRANDTZAEG P.: "Activated T lymphocytes in the celiac lesion: Non proliferative activation (CD25) of CD24 positive apha/beta cells in the lamina propria but proliferation (Ki-67) of alpha/beta and gamma/delta cells in the epithelium", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, no. 2, 1993, pages 505 - 510, XP002094962 *
KOZENITZKY L. ET AL.: "Immunomodulatory effects of AS101 on interleukin-2 production and T-lymphocyte function of lymphocytes treated with psoralens and ultraviolet A", PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE, vol. 9, no. 1, 1992, pages 24 - 28, XP002094960 *
MONTERO R. ET AL.: "AS-101: a modulator of in vitro T-cel proliferation", ANTI-CANCER DRUGS, vol. 4, no. 3, 1993, pages 351 - 354, XP002094966 *
ULLRICH S.E.: "Photoinactivation of t-cell function with psoralen and uvA radiation suppresses the induction of experimental murine graf-versus-host disease accross Major Histocompatibility barriers", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 96, no. 3, 1991, pages 303 - 308, XP002094961 *
WINKELSTEIN A.: "Murine B-lymphocyte colony formation: the effects of cyclophosphamide and azathiopirine", IMMUNOLOGY, vol. 46, - 1982, gb, pages 827 - 832, XP002094965 *

Also Published As

Publication number Publication date
CA2296366A1 (en) 1999-01-28
EP1005531A2 (en) 2000-06-07
AU748074B2 (en) 2002-05-30
CN1270630A (en) 2000-10-18
WO1999003976A2 (en) 1999-01-28
JP2003520563A (en) 2003-07-08
AU8577698A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
WO1999003976A3 (en) Method of treating leukocytes, leukocyte compositions and methods of use thereof
ES2113980T3 (en) SOLUBLE LINKS FOR CD40.
EP1409547A4 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
DE69929232D1 (en) VIRUSELY PARTICLES FOR INDUCING AUTOANTIC BODIES
WO2003083041A8 (en) Cripto-specific antibodies
DK1225870T3 (en) Composition and method of cancer antigen immunotherapy
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
NO943967D0 (en) Suppression of proliferative responses and induction of tolerance by polymorphic class II MHC allopeptides
EP1218030A4 (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
KR890700353A (en) Immunosuppression of the immune toxin
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
EP1037918A4 (en) Method and composition to enhance the efficacy of a vaccine using chemokines
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
CA2346735A1 (en) Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
EP1100515A4 (en) $i(EX VIVO) TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer
Afifi REJECTION OF NORMAL AND NEOPLASTIC HEMOPOIETIC CELLS BY LETHALLY IRRADIATED MICE.
UA32241A (en) Method for treating inflammations in experiment
UA32358A (en) Method for treatment of hypertension
AU2002329036A1 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98809097.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2296366

Country of ref document: CA

Ref document number: 2296366

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 85776/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998936943

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998936943

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 85776/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998936943

Country of ref document: EP